Valion Bio (VBIO) Retained Earnings (2021 - 2026)

Valion Bio has reported Retained Earnings for 6 years, with the latest figure at $70.8 million in Q2 2026.

• On a quarterly basis, Retained Earnings rose 40.69% year-over-year to $70.8 million in Q2 2026; TTM through Jun 2026 was $70.8 million, a 40.69% increase from a year earlier, with the FY2025 full-year figure at $69.4 million, up 50.61% from the prior year.
• Retained Earnings was $70.8 million for Q2 2026 at Valion Bio, up from $69.4 million in the prior quarter.
• The five-year high for Retained Earnings was $70.8 million in Q2 2026, with the low at $32.9 million in Q1 2022.
• Average Retained Earnings over 5 years is $44.6 million, with a median of $41.5 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2025: Retained Earnings rose 1.39% in 2022, then jumped 50.61% in 2025.
• Over 5 years, Retained Earnings stood at $33.3 million in 2022, then climbed by 24.63% to $41.5 million in 2023, then advanced by 11.12% to $46.1 million in 2024, then jumped by 50.61% to $69.4 million in 2025, then rose by 1.96% to $70.8 million in 2026.
• The last three Retained Earnings figures came in at $70.8 million (Q2 2026), $69.4 million (Q4 2025), and $53.0 million (Q3 2025), per Business Quant data.